The U.S. House of Representatives passed the 21st Century Cures Act, H.R. 6, last month with an overwhelming bipartisan vote of 344-77. This legislation includes key IDSA priorities, such as the Limited Population Antibacterial Drug (LPAD) approval mechanism, a provision to improve the process for updating antimicrobial susceptibility breakpoints, increased funding for the National Institutes of Health (NIH), and an increase to the annual limit for the NIH loan repayment program. Over the last few years, IDSA members have undertaken significant advocacy—through emails, phone calls and in person meetings with congressional staff and members of Congress—in support of these policies, and these efforts have been critical to the Society’s success in advancing these priorities. |
The U.S. Senate is developing its own legislation—Innovations for Healthier Americans—that will be similar in scope to Cures. IDSA is now advocating for inclusion of our priorities in this bill.
As part of these efforts, IDSA Antimicrobial Resistance Committee member, Helen Boucher, MD, FIDSA, spoke at a July 28 Senate briefing in support of the Senate LPAD legislation (the Promise for Antibiotics and Therapeutics for Health, or PATH Act, S. 185). She was joined by Janet Woodcock, MD, of the Food and Drug Administration (FDA), Prabha Fernandes of Cempra, and Alan Coukell of The Pew Charitable Trusts. The briefing garnered over 70 attendees, including key Senate staff and representatives from other stakeholder organizations.
You can help us advance the PATH Act by taking a minute or two to email your Senators through this link.
< Previous Article | Next Article >